Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0194-0499, cagrilintide, and semaglutide in alcohol-related liver disease
2023-508170-28-00Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- May 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides, Hormonal Peptides → Native Peptides → Peptides
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of nn9500, cagrilintide and semaglutide in alcoholic liver disease (ALD) and alcohol use disorder (AUD) (6 arms), sponsored by Novo Nordisk. Primary endpoint: Change in Enhanced Liver Fibrosis (ELF). Started May 2024; status: completed.
02
Drugs
03
Conditions
alcoholic liver disease (ALD)alcohol use disorder (AUD)
Beyond the preview
Go deeper on 2023-508170-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508170-28-00.